<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36395069</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>22</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2222-1751</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Emerging microbes &amp; infections</Title><ISOAbbreviation>Emerg Microbes Infect</ISOAbbreviation></Journal><ArticleTitle>Non-neutralizing monoclonal antibody targeting VP2 EF loop of Coxsackievirus A16 can protect mice from lethal attack via Fc-dependent effector mechanism.</ArticleTitle><Pagination><StartPage>2149352</StartPage><MedlinePgn>2149352</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2149352</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1080/22221751.2022.2149352</ELocationID><Abstract><AbstractText>Coxsackievirus A16 (CA16), a main causative agent of hand, foot, and mouth disease (HFMD), has become a serious public health concern in the Asia-Pacific region. Here, we generated an anti-CA16 monoclonal antibody, DMA2017, derived from an epidemic strain CA16. Surprisingly, although DMA2017 could not neutralize the original and circulating CA16 strains <i>in vitro</i>, the passive transfer of DMA2017 (10 Î¼g/g) could protect suckling mice from a lethal challenge with CA16 <i>in vivo</i>. Then, we confirmed the protective effect of DMA2017 relies on the Fc-dependent effector functions, such as antibody-dependent cellular cytotoxicity (ADCC). The linear epitope of DMA2017 was mapped by phage display technique to a conserved patch spanning residues 143-148 (NSHPPY) of the VP2 EF-loop of CA16. DMA2017 could inhibit the binding of the antibodies present in the sera of naturally infected children to CA16, indicating that the epitope of DMA2017 is immunodominant for CA16. Our results confirm, for the first time, that a potential preventive and therapeutic effect could be mediated by a non-neutralizing antibody elicited against CA16. These findings bring a hitherto understudied protective role of non-neutralizing antibodies during viral infections into the spotlight and provide a new perspective on the design and evaluation of CA16 vaccines.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Ruixiao</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>NHC Key Laboratory of Research on Quality and Standardization of Biotech Products; NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>An</LastName><ForeName>Chaoqiang</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Beijing minhai Biotechnology Co. Ltd, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>NHC Key Laboratory of Research on Quality and Standardization of Biotech Products; NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yiping</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>NHC Key Laboratory of Research on Quality and Standardization of Biotech Products; NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ge</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Autobio Diagnostics Co. Ltd, Zhengzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>NHC Key Laboratory of Research on Quality and Standardization of Biotech Products; NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bian</LastName><ForeName>Lianlian</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>NHC Key Laboratory of Research on Quality and Standardization of Biotech Products; NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Yalin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>NHC Key Laboratory of Research on Quality and Standardization of Biotech Products; NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Siyuan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Beijing minhai Biotechnology Co. Ltd, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Qiaohui</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Autobio Diagnostics Co. Ltd, Zhengzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Qunying</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>NHC Key Laboratory of Research on Quality and Standardization of Biotech Products; NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Zhenglun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>NHC Key Laboratory of Research on Quality and Standardization of Biotech Products; NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Emerg Microbes Infect</MedlineTA><NlmUniqueID>101594885</NlmUniqueID><ISSNLinking>2222-1751</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="Y">Viral Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="Y">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coxsackievirus A16</Keyword><Keyword MajorTopicYN="N">Fc-dependent effector functions</Keyword><Keyword MajorTopicYN="N">antibody-dependent cellular cytotoxicity</Keyword><Keyword MajorTopicYN="N">epitope</Keyword><Keyword MajorTopicYN="N">non-neutralizing monoclonal antibody</Keyword><Keyword MajorTopicYN="N">protective effect</Keyword></KeywordList><CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>17</Day><Hour>14</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>12</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36395069</ArticleId><ArticleId IdType="pmc">PMC9788719</ArticleId><ArticleId IdType="doi">10.1080/22221751.2022.2149352</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Perera D, Yusof MA, Podin Y, et al. . Molecular phylogeny of modern coxsackievirus A16. Arch Virol. 2007;152(6):1201â1208.</Citation><ArticleIdList><ArticleId IdType="pubmed">17308978</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox B, Hand LF.. Foot, and mouth disease. JAMA. 2018 Dec 18;320(23):2492.</Citation><ArticleIdList><ArticleId IdType="pubmed">30561482</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao QY, Wang Y, Bian L, et al. . EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD). Expert Rev Vaccines. 2016 May;15(5):599â606.</Citation><ArticleIdList><ArticleId IdType="pubmed">26732723</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosoya M, Kawasaki Y, Sato M, et al. . Genetic diversity of coxsackievirus A16 associated with hand, foot, and mouth disease epidemics in Japan from 1983 to 2003. J Clin Microbiol. 2007 Jan;45(1):112â120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1828949</ArticleId><ArticleId IdType="pubmed">17093028</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwai M, Masaki A, Hasegawa S, et al. . Genetic changes of coxsackievirus A16 and enterovirus 71 isolated from hand, foot, and mouth disease patients in Toyama, Japan between 1981 and 2007. Jpn J Infect Dis. 2009 Jul;62(4):254â259.</Citation><ArticleIdList><ArticleId IdType="pubmed">19628900</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, He Y, Yang H, et al. . Genetic characteristics of human enterovirus 71 and coxsackievirus A16 circulating from 1999 to 2004 in Shenzhen, People's Republic of China. J Clin Microbiol. 2005 Aug;43(8):3835â3839.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1233905</ArticleId><ArticleId IdType="pubmed">16081920</ArticleId></ArticleIdList></Reference><Reference><Citation>Mutterer M Sicklesgm, Plager H Feorinop.. Recently classified types of Coxsackie virus, group A; behavior in tissue culture. Proc Soc Exp Biol Med. 1955 Nov;90(2):529â531.</Citation><ArticleIdList><ArticleId IdType="pubmed">13273503</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q, Wang Y, Yao X, et al. . Coxsackievirus A16: epidemiology, diagnosis, and vaccine. Hum Vaccin Immunother. 2014;10(2):360â367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4185891</ArticleId><ArticleId IdType="pubmed">24231751</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LY, Lin TY, Huang YC, et al. . Comparison of enterovirus 71 and coxsackie-virus A16 clinical illnesses during the Taiwan enterovirus epidemic, 1998. Pediatr Infect Dis J. 1999 Dec;18(12):1092â1096.</Citation><ArticleIdList><ArticleId IdType="pubmed">10608631</ArticleId></ArticleIdList></Reference><Reference><Citation>Goto K, Sanefuji M, Kusuhara K, et al. . Rhombencephalitis and coxsackievirus A16. Emerg Infect Dis. 2009 Oct;15(10):1689â1691.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2866411</ArticleId><ArticleId IdType="pubmed">19861078</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma S, Zhang Y, Du C, et al. . Dynamic constitution of the pathogens inducing encephalitis in hand, foot and mouth disease in Kunming, 2009-2011. Jpn J Infect Dis. 2015;68(6):504â510.</Citation><ArticleIdList><ArticleId IdType="pubmed">25866107</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao X, Mao Q, Li Y, et al. . Poorly neutralizing polyclonal antibody in vitro against coxsackievirus A16 circulating strains can prevent a lethal challenge in vivo. Hum Vaccin Immunother. 2018 May 4;14(5):1275â1282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5989894</ArticleId><ArticleId IdType="pubmed">29337652</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogt MR, Dowd KA, Engle M, et al. . Poorly neutralizing cross-reactive antibodies against the fusion loop of West Nile virus envelope protein protect in vivo via Fcgamma receptor and complement-dependent effector mechanisms. J Virol. 2011 Nov;85(22):11567â11580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3209272</ArticleId><ArticleId IdType="pubmed">21917960</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q, Wang Y, Gao R, et al. . A neonatal mouse model of coxsackievirus A16 for vaccine evaluation. J Virol. 2012 Nov;86(22):11967â11976.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3486452</ArticleId><ArticleId IdType="pubmed">22951825</ArticleId></ArticleIdList></Reference><Reference><Citation>Du R, Mao Q, Hu Y, et al. . A potential therapeutic neutralization monoclonal antibody specifically against multi-coxsackievirus A16 strains challenge. Hum Vaccin Immunother. 2019;15(10):2343â2350.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6816366</ArticleId><ArticleId IdType="pubmed">30735461</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren J, Wang X, Zhu L, et al. . Structures of Coxsackievirus A16 capsids with native antigenicity: implications for particle expansion, receptor binding, and immunogenicity. J Virol. 2015 Oct;89(20):10500â10511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4580203</ArticleId><ArticleId IdType="pubmed">26269176</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Yan K, Feng Y, et al. . A virus-like particle vaccine for coxsackievirus A16 potently elicits neutralizing antibodies that protect mice against lethal challenge. Vaccine. 2012 Oct 19;30(47):6642â6648.</Citation><ArticleIdList><ArticleId IdType="pubmed">22959985</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Z, Mao Q, Gao Q, et al. . Establishing China's national standards of antigen content and neutralizing antibody responses for evaluation of enterovirus 71 (EV71) vaccines. Vaccine. 2011 Dec 6;29(52):9668â9674.</Citation><ArticleIdList><ArticleId IdType="pubmed">22015395</ArticleId></ArticleIdList></Reference><Reference><Citation>A guide to clinical management and public health response for hand, foot and mouth disease (HFMD) . Available from: http://www.wpro.who.int/publications/docs/Guidanceforthec linicalmanagementofHFMD.pdf.</Citation></Reference><Reference><Citation>Japanese Encephalitis: Vaccine Preventable Diseases Surveillance Standards . Available from:https://www.who.int/publications/m/item/vaccine-preventable-diseases-surveillance-standards-je.</Citation></Reference><Reference><Citation>Takada A, Ebihara H, Jones S, et al. . Protective efficacy of neutralizing antibodies against Ebola virus infection. Vaccine. 2007 Jan 22;25(6):993â999.</Citation><ArticleIdList><ArticleId IdType="pubmed">17055127</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LY, King CC, Hsu KH, et al. . Risk factors of enterovirus 71 infection and associated hand, foot, and mouth disease/herpangina in children during an epidemic in Taiwan. Pediatrics. 2002 Jun;109(6):e88.</Citation><ArticleIdList><ArticleId IdType="pubmed">12042582</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin J, Ma H, Xu L, et al. . Development of a Coxsackievirus A16 neutralization assay based on pseudoviruses for measurement of neutralizing antibody titer in human serum. J Virol Methods. 2013 Feb;187(2):362â367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7112850</ArticleId><ArticleId IdType="pubmed">23178532</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizuta K, Abiko C, Murata T, et al. . Frequent importation of enterovirus 71 from surrounding countries into the local community of Yamagata, Japan, between 1998 and 2003. J Clin Microbiol. 2005 Dec;43(12):6171â6175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1317214</ArticleId><ArticleId IdType="pubmed">16333123</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MS, Chang LY.. Development of enterovirus 71 vaccines. Expert Rev Vaccines. 2010 Feb;9(2):149â156.</Citation><ArticleIdList><ArticleId IdType="pubmed">20109026</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Shi J, Huang X, et al. . A murine model of coxsackievirus A16 infection for anti-viral evaluation. Antiviral Res. 2014 May;105:26â31.</Citation><ArticleIdList><ArticleId IdType="pubmed">24583030</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Z, Zhao J, Zhao Y, et al. . Hemagglutinin-specific non-neutralizing antibody is essential for protection provided by inactivated and viral-vectored H7N9 avian influenza vaccines in chickens. Front Vet Sci. 2020 Jan 9;6: 482.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6962174</ArticleId><ArticleId IdType="pubmed">31998763</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunn BM, Yu WH, Karim MM, et al. . A role for Fc function in therapeutic monoclonal antibody-mediated protection against ebola virus. Cell Host Microbe. 2018 Aug 8;24(2):221â233. e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6298217</ArticleId><ArticleId IdType="pubmed">30092199</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimmerjahn F, Gordan S, Lux A.. FcÎ³r dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities. Trends Immunol. 2015 Jun;36(6):325â336.</Citation><ArticleIdList><ArticleId IdType="pubmed">25981969</ArticleId></ArticleIdList></Reference><Reference><Citation>Bournazos S, Gupta A, Ravetch JV.. The role of IgG Fc receptors in antibody-dependent enhancement. Nat Rev Immunol. 2020 Oct;20(10):633â643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7418887</ArticleId><ArticleId IdType="pubmed">32782358</ArticleId></ArticleIdList></Reference><Reference><Citation>DiLillo DJ, Tan GS, Palese P, et al. . Broadly neutralizing hemagglutinin stalk-specific antibodies require FcÎ³R interactions for protection against influenza virus in vivo. Nat Med. 2014 Feb;20(2):143â151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3966466</ArticleId><ArticleId IdType="pubmed">24412922</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilinykh PA, Huang K, Santos RI, et al. . Non-neutralizing antibodies from a marburg infection survivor mediate protection by Fc-effector functions and by enhancing efficacy of other antibodies. Cell Host Microbe. 2020 Jun 10;27(6):976â991. e11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7292764</ArticleId><ArticleId IdType="pubmed">32320678</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Wang H, Shih SR, et al. . The efficacy of viral capsid inhibitors in human enterovirus infection and associated diseases. Curr Med Chem. 2007;14(8):847â856.</Citation><ArticleIdList><ArticleId IdType="pubmed">17430140</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi J, Huang X, Liu Q, et al. . Identification of conserved neutralizing linear epitopes within the VP1 protein of coxsackievirus A16. Vaccine. 2013 Apr 19;31(17):2130â2136.</Citation><ArticleIdList><ArticleId IdType="pubmed">23499595</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Peng W, Ren J, et al. . A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol. 2012 Mar 4;19(4):424â429.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3378640</ArticleId><ArticleId IdType="pubmed">22388738</ArticleId></ArticleIdList></Reference><Reference><Citation>Plevka P, Lim PY, Perera R, et al. . Neutralizing antibodies can initiate genome release from human enterovirus 71. Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):2134â2139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3926013</ArticleId><ArticleId IdType="pubmed">24469789</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L, He D, Yang L, et al. . A broadly cross-protective vaccine presenting the neighboring epitopes within the VP1 GH loop and VP2 EF loop of enterovirus 71. Sci Rep. 2015 Aug 5;5: 12973.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4525384</ArticleId><ArticleId IdType="pubmed">26243660</ArticleId></ArticleIdList></Reference><Reference><Citation>Plevka P, Perera R, Cardosa J, et al. . Crystal structure of human enterovirus 71. Science. 2012 Jun 8;336(6086):1274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3448362</ArticleId><ArticleId IdType="pubmed">22383808</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Chou AH, Lien SP, et al. . Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Vaccine. 2011 Jun 10;29(26):4362â4372.</Citation><ArticleIdList><ArticleId IdType="pubmed">21501643</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L, He D, Li Z, et al. . Protection against lethal enterovirus 71 challenge in mice by a recombinant vaccine candidate containing a broadly cross-neutralizing epitope within the VP2 EF loop. Theranostics. 2014 Feb 18;4(5):498â513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3964443</ArticleId><ArticleId IdType="pubmed">24669278</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiener TK, Jia Q, Lim XF, et al. . Characterization and specificity of the linear epitope of the enterovirus 71 VP2 protein. Virol J. 2012 Feb 24;9: 55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3307493</ArticleId><ArticleId IdType="pubmed">22361222</ArticleId></ArticleIdList></Reference><Reference><Citation>Breschkin AM, Ahern J, White DO.. Antigenic determinants of influenza virus hemagglutinin. VIII. topography of the antigenic regions of influenza virus hemagglutinin determined by competitive radioimmunoassay with monoclonal antibodies. Virology. 1981 Aug;113(1):130â140.</Citation><ArticleIdList><ArticleId IdType="pubmed">6168097</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>